Free tool
FAERS Monitor: Depen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019854 or its brand name (Depen, Penicillamine). Reports on generic versions are filed under their own applications.
Reports
742
Serious
599
81% of reports
Hospitalization
206
Death reported
70
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity177
- drug ineffective169
- arthralgia150
- joint swelling142
- inflammation111
- diarrhoea88
- nausea87
- hypersensitivity79
- drug intolerance78
- anaphylactic reaction77
- headache76
- urticaria71
- off label use70
- treatment failure69
- acute kidney injury68
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 22 |
| 2006 | 9 |
| 2007 | 15 |
| 2008 | 17 |
| 2009 | 21 |
| 2010 | 21 |
| 2011 | 23 |
| 2012 | 12 |
| 2013 | 8 |
| 2014 | 14 |
| 2015 | 16 |
| 2016 | 28 |
| 2017 | 46 |
| 2018 | 58 |
| 2019 | 74 |
| 2020 | 104 |
| 2021 | 65 |
| 2022 | 42 |
| 2023 | 40 |
| 2024 | 29 |
| 2025 | 35 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,417 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| inflammationSignal | 111 | 61.1 | 51.5 | 6,504 |
| anaphylactic reactionSignal | 77 | 39.6 | 32.0 | 2,859 |
| joint swellingSignal | 142 | 33.4 | 28.8 | 4,449 |
| drug hypersensitivitySignal | 177 | 25.9 | 22.8 | 4,256 |
| treatment failureSignal | 69 | 23.6 | 18.9 | 1,477 |
| drug intoleranceSignal | 78 | 22.9 | 18.6 | 1,618 |
| acute kidney injurySignal | 68 | 12.6 | 10.0 | 720 |
| hypersensitivitySignal | 79 | 12.1 | 9.8 | 798 |
| urticariaSignal | 71 | 12.0 | 9.6 | 712 |
| arthralgiaSignal | 150 | 10.2 | 8.9 | 1,264 |
| diarrhoeaSignal | 88 | 3.9 | 3.2 | 190 |
| drug ineffectiveSignal | 169 | 3.6 | 3.2 | 342 |
| headacheSignal | 76 | 3.4 | 2.8 | 133 |
| nauseaSignal | 87 | 3.1 | 2.6 | 128 |
| off label useSignal | 70 | 2.3 | 1.8 | 50 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.